FDA strategic plan includes focus on health IT

The FDA’s four-year strategic plan includes several health IT-related goals.

For example, the agency is looking to develop a real-time information sharing system that would be available to regulators worldwide.

The agency will work with these entities to identify critical data elements, such as unique facility identifiers, to better standardize reporting and facilitate data exchange. Also, the report says the agency will expand its capabilities in intelligence-gathering and use—with an increased focus on risk analytics and modernized IT capabilities.

“These capabilities will enable FDA to more effectively allocate our resources based on risk, leveraging the combined efforts of government, industry and public- and private-sector third parties," according to the plan.

Also, the FDA is looking to bolster its surveillance systems that track adverse event reports utilizing EHRs, insurance claims databases and registries.

Read more.

 

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.